SEARCH

SEARCH BY CITATION

References

  • 1
    Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005; 34: 13291339.
  • 2
    U.S.Census Bureau. B05006. Place of birth for the foreign-born population–universe: foreign-born population excluding population born at sea. http://factfinder.census.gov/servlet/DTTable?_bm=y&-geo_id= 01000US&-ds_name=ACS_2006_EST_G00_&-_lang=en&-mt_ name=ACS_2006_EST_G2000_B05006&-mt_name=ACS_2006_ EST_G2000_C05006&-format=&-CONTEXT=dt.
  • 3
    Weinbaum C, Lyerla R, Margolis HS; Centers for Disease Control and Prevention. Guidelines for prevention and control of infections with hepatitis viruses in correctional settings. MMWR Recomm Rep 2003; 52 (No. RR-1): 136.
  • 4
    Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan GM, et al. Hepatitis B Prevalence in the U.S. in era of vaccination. Abstract #723. In: 45th Annual Meeting of the Infectious Diseases Society of America; San Diego CA; October 4-7, 2007.
  • 5
    Sabol WJ, Minton ED, Harrison PM. Prison and jail inmates at midyear 2006. Washington, DC: US Department of Justice, Bureau of Justice Statistics, Office of Justice Programs; 2007.
  • 6
    Blumberg BS, Alter HJ, Visnich S. A “new” antigen in leukemia sera. JAMA 1965; 191: 541546.
  • 7
    Perry E, Chaudhary RK, Cleary TE, Roughley FR. Hepatitis B surface antigen and its subtypes in an institution for the mentally retarded. Can Med Assoc J 1975; 112: 4648.
  • 8
    Feinman SV, Krassnitzky O, Sinclair JC, Wrobel DM, Berris B. Prevalence and significance of hepatitis B surface antigen in a general hospital. Can Med Assoc J 1975; 112: 4345.
  • 9
    Saslow AR, Hammon WM, Rycheck RR, Streiff E, Lewis J. “Hippie” hepatitis: an epidemiologic investigation conducted within a population of “street-people”. Am J Epidemiol 1975; 101: 211219.
  • 10
    Szmuness W, Hoofnagle JH, Stevens CE, Prince AM. Antibody against the hepatitis type B core antigen. A new tool for epidemiologic studies. Am J Epidemiol 1976; 104: 256262.
  • 11
    Alter HJ, Holland PV, Purcell RH, Lander JJ, Feinstone SM, Morrow AG, et al. Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Ann Intern Med 1972; 77: 691699.
  • 12
    Code of Federal Regulations. Title 21. Food and Drugs. Section 610.40. Test for hepatitis B surface antigen; 2007.
  • 13
    Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001; 50 (RR-5): 143.
  • 14
    Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991; 40 (RR-13): 125.
  • 15
    Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54 (RR-16): 123.
  • 16
    Centers for Disease Control and Prevention. Protection against viral hepatitis. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1990; 39 (RR-2): 126.
  • 17
    Aberg JA, Gallant JE, Anderson J, Oleske JM, Libman H, Currier JS, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2004; 39: 609629.
  • 18
    Wasley A, Grytdal S, Gallagher K. Surveillance for acute viral hepatitis–United States, 2006. MMWR Surveill Summ 2008; 57: 124.
  • 19
    Centers for Disease Control and Prevention. Acute hepatitis B among children and adolescents–United States, 1990–2002. MMWR Morb Mortal Wkly Rep 2004; 53: 10151018.
  • 20
    Vogt T, Wise ME, Shih H, Williams IT. Hepatitis B mortality in the United States, 1990-2004 (abstract). 45th Annual Meeting of Infectious Diseases Society of America; San Diego, CA; October 4-7, 2007; 172.
  • 21
    Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593601.
  • 22
    Sulkowski MS. Management of hepatic complications in HIV-infected persons. J Infect Dis 2008; 197(Suppl 3): S279S293.
  • 23
    Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44(1 Suppl ): S6S9.
  • 24
    Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al.; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Part II: immunization of adults. MMWR Recomm Rep 2006; 55 (RR-16): 133.
  • 25
    Mast EE, Ward JW. Hepatitis B vaccine. In: PlotkinSA, OrensteinWA, OffitPA, eds. Vaccines. 5th ed. Philadelphia, PA: Saunders; 2008.
  • 26
    Madani TA. Trend in incidence of hepatitis B virus infection during a decade of universal childhood hepatitis B vaccination in Saudi Arabia. Trans R Soc Trop Med Hyg 2007; 101: 278283.
  • 27
    Hollinger BF, Bell B, Levy-Bruhl D, Shouval D, Wiersma S, Van Damme P. Hepatitis A and B vaccination and public health. J Viral Hepat 2007; 14(Suppl 1): 15.
  • 28
    Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006; 28: 112125.
  • 29
    Tsebe KV, Burnett RJ, Hlungwani NP, Sibara MM, Venter PA, Mphahlele MJ. The first five years of universal hepatitis B vaccination in South Africa: evidence for elimination of HBsAg carriage in under 5-year-olds. Vaccine 2001; 19: 39193926.
  • 30
    Chang ET, Keegan TH, Gomez SL, Le GM, Clarke CA, So SK, et al. The burden of liver cancer in Asians and Pacific Islanders in the Greater San Francisco Bay Area, 1990 through 2004. Cancer 2007; 109: 21002108.
  • 31
    Perz JF, Openo K, Ahmed F, Bell BP. Trends in mortality from liver cancer in the United States, 1993-2002. J Clin Virol 2006; 36 (Suppl. 2): S176.
  • 32
    Hainaut P, Boyle P. Curbing the liver cancer epidemic in Africa. Lancet 2008; 371: 367368.
  • 33
    Tandon BN, Acharya SK, Tandon A. Epidemiology of hepatitis B virus infection in India. Gut 1996; 38(Suppl 2): S56S59.
  • 34
    Centers for Disease Control and Prevention. Recommendation of the Immunization Practices Advisory Committee (ACIP). Inactivated hepatitis B virus vaccine. MMWR Morb Mortal Wkly Rep 1982; 31: 317318.
  • 35
    Hurie MB, Mast EE, Davis JP. Horizontal transmission of hepatitis B virus infection to United States-born children of Hmong refugees. Pediatrics 1992; 89: 269273.
  • 36
    Mahoney FJ, Lawrence M, Scott C, Le Q, Lambert S, Farley TA. Continuing risk for hepatitis B virus transmission among Southeast Asian infants in Louisiana. Pediatrics 1995; 96: 11131116.
  • 37
    Franks AL, Berg CJ, Kane MA, Browne BB, Sikes RK, Elsea WR, et al. Hepatitis B infection among children born in the United States to southeast Asian refugees. N Engl J Med 1989; 321: 1305.
  • 38
    Bower WA, Finelli L, Goldstein ST. Hepadnaviridae: hepatitis B and hepatitis D virus. In: LongS, PickeringL, ProberCG, eds. Principles and Practice of Pediatric Infectious Diseases. 3rd ed. New York, NY: Churchill Livingston; 2007.: 10861097.
  • 39
    Heathcote J, Gateau P, Sherlock S. Role of hepatitis-B antigen carriers in non-parenteral transmission of the hepatitis-B virus. Lancet 1974; 2: 370371.
  • 40
    Bernier RH, Sampliner R, Gerety R, Tabor E, Hamilton F, Nathanson N. Hepatitis B infection in households of chronic carriers of hepatitis B surface antigen: factors associated with prevalence of infection. Am J Epidemiol 1982; 116: 199211.
  • 41
    Irwin GR, Allen AM, Bancroft WH, Karwacki JJ, Pinkerton RH, Russell PK. Hepatitis B antigen and antibody. Occurrence in families of asymptomatic HB AG carriers. JAMA 1974; 227: 10421043.
  • 42
    Chakravarty R, Chowdhury A, Chaudhuri S, Santra A, Neogi M, Rajendran K, et al. Hepatitis B infection in Eastern Indian families: need for screening of adult siblings and mothers of adult index cases. Public Health 2005; 119: 647654.
  • 43
    Seage GR III, Mayer KH, Lenderking WR, Wold C, Gross M, Goldstein R, et al. HIV and hepatitis B infection and risk behavior in young gay and bisexual men. Public Health Rep 1997; 112: 158167.
  • 44
    MacKellar DA, Valleroy LA, Secura GM, McFarland W, Shehan D, Ford W, et al. Two decades after vaccine license: hepatitis B immunization and infection among young men who have sex with men. Am J Public Health 2001; 91: 965971.
  • 45
    Weinbaum CM, Lyerla R, MacKellar DA, Valleroy LA, Secura GM, Behel SK, et al. The Young Men's Survey Phase II: hepatitis B immunization and infection among young men who have sex with men. Am J Public Health 2008; 98: 839845.
  • 46
    Dietzman DE, Harnisch JP, Ray CG, Alexander ER, Holmes KK. Hepatitis B surface antigen (HBsAg) and antibody to HBsAg. Prevalence in homosexual and heterosexual men. JAMA 1977; 238: 26252626.
  • 47
    Schreeder MT, Thompson SE, Hadler SC, Berquist KR, Zaidi A, Maynard JE, et al. Hepatitis B in homosexual men: prevalence of infection and factors related to transmission. J Infect Dis 1982; 146: 715.
  • 48
    Szmuness W, Much I, Prince AM, Hoofnagle JH, Cherubin CE, Harley EJ, et al. On the role of sexual behavior in the spread of hepatitis B infection. Ann Intern Med 1975; 83: 489495.
  • 49
    Lopez-Zetina J, Kerndt P, Ford W, Woerhle T, Weber M. Prevalence of HIV and hepatitis B and self-reported injection risk behavior during detention among street-recruited injection drug users in Los Angeles County, 1994-1996. Addiction 2001; 96: 589595.
  • 50
    Kunches LM, Craven DE, Werner BG. Seroprevalence of hepatitis B virus and delta agent in parenteral drug abusers. Immunogenicity of hepatitis B vaccine. Am J Med 1986; 81: 591595.
  • 51
    Raimondo G, Smedile A, Gallo L, Balbo A, Ponzetto A, Rizzetto M. Multicentre study of prevalence of HBV-associated delta infection and liver disease in drug-addicts. Lancet 1982; 1: 249251.
  • 52
    Zeldis JB, Jain S, Kuramoto IK, Richards C, Sazama K, Samuels S, et al. Seroepidemiology of viral infections among intravenous drug users in northern California. West J Med 1992; 156: 3035.
  • 53
    Mangla JC, Kim YM, Brown MR, Schwob D, Hanson SE. Liver tests, HB-Ag and HB-Ab in asymptomatic drug addicts. Am J Gastroenterol 1976; 65: 121126.
  • 54
    Seeff LB, Zimmerman HJ, Wright EC, Schiff ER, Kiernan T, Leevy CM, et al. Hepatic disease in asymptomatic parenteral narcotic drug abusers: a Veterans Administration collaborative study. Am J Med Sci 1975; 270: 4147.
  • 55
    Cherubin CE, Schaefer RA, Rosenthal WS, McGinn T, Forte F, Purcell R, et al. The natural history of liver disease in former drug users. Am J Med Sci 1976; 272: 244253.
  • 56
    Blanck RR, Ream N, Conrad M. Hepatitis B antigen and antibody in heroin users. Am J Gastroenterol 1979; 71: 164167.
  • 57
    Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003; 188: 571577.
  • 58
    Fleming DT, Zambrowski A, Fong F, Lombard A, Mercedes L, Miller C, et al. Surveillance programs for chronic viral hepatitis in three health departments. Public Health Rep 2006; 121: 2335.
  • 59
    Bialek SR, Bower WA, Mottram K, Purchase D, Nakano T, Nainan O, et al. Risk factors for hepatitis B in an outbreak of hepatitis B and D among injection drug users. J Urban Health 2005; 82: 468478.
  • 60
    Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol 1999; 149: 203213.
  • 61
    Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 19211926.
  • 62
    McGovern BH. The epidemiology, natural history and prevention of hepatitis B: implications of HIV coinfection. Antivir Ther 2007; 12(Suppl 3): H3H13.
  • 63
    Santiago-Munoz P, Roberts S, Sheffield J, McElwee B, Wendel GD Jr. Prevalence of hepatitis B and C in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol 2005; 193 (3 Pt 2): 12701273.
  • 64
    Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 2004; 18: 20392045.
  • 65
    Hadler SC, Judson FN, O'Malley PM, Altman NL, Penley K, Buchbinder S, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991; 163: 454459.
  • 66
    Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519528.
  • 67
    Saab S, Dong MH, Joseph TA, Tong MJ. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. HEPATOLOGY 2007; 46: 10491056.
  • 68
    Centers for Disease Control and Prevention. Screening for chronic hepatitis B among Asian/Pacific Islander populations—New York City, 2005. MMWR Morb Mortal Wkly Rep 2006; 55: 505509.
  • 69
    Choe JH, Taylor VM, Yasui Y, Burke N, Nguyen T, Acorda E, et al. Health care access and sociodemographic factors associated with hepatitis B testing in Vietnamese American men. J Immigr Minor Health 2006; 8: 193201.
  • 70
    Taylor VM, Jackson JC, Chan N, Kuniyuki A, Yasui Y. Hepatitis B knowledge and practices among Cambodian American women in Seattle, Washington. J Community Health 2002; 27: 151163.
  • 71
    Lin SY, Chang ET, So SK. Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California. HEPATOLOGY 2007; 46: 10341040.
  • 72
    Lok ASF, McMahon BJ. Chronic hepatitis B: AASLD practice guidelines. HEPATOLOGY 2007; 45: 507539.
  • 73
    Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25: 472489.
  • 74
    The EASL Jury. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003; 38: 533540.
  • 75
    Bruix J, Sherman M. Management of hepatocellular carcinoma. HEPATOLOGY 2005; 42: 12081236.
  • 76
    Advisory Committee on Immunization Practices of CDC; Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55 (RR-7): 123.
  • 77
    Ohnishi K, Iida S, Iwama S, Goto N, Nomura F, Takashi M, et al. The effect of chronic habitual alcohol intake on the development of liver cirrhosis and hepatocellular carcinoma: relation to hepatitis B surface antigen carriage. Cancer 1982; 49: 672677.
  • 78
    Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28: 930938.
  • 79
    Wilson JM, Jungner G. Principles and practice of screening for disease. Geneva, Switzerland: World Health Organization, 1968.
  • 80
    Hutton DW, Tan D, So SK, Brandeau ML. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med 2007; 147: 460469.
  • 81
    Paltiel AD, Weinstein MC, Kimmel AD, Seage GR III, Losina E, Zhang H, et al. Expanded screening for HIV in the United States–an analysis of cost-effectiveness. N Engl J Med 2005; 352: 586595.
  • 82
    O'Connor PJ, Rush WA, Cherney LM, Pronk NP. Screening for diabetes mellitus in high-risk patients: cost, yield, and acceptability. Eff Clin Pract 2001; 4: 271277.
  • 83
    Keren R, Helfand M, Homer C, McPhillips H, Lieu TA. Projected cost-effectiveness of statewide universal newborn hearing screening. Pediatrics 2002; 110(5): 855864.
  • 84
    Feuchtbaum L, Cunningham G. Economic evaluation of tandem mass spectrometry screening in California. Pediatrics 2006; 117 (5 Pt 2): S280S286.
  • 85
    Ball RH, Caughey AB, Malone FD, Nyberg DA, Comstock CH, Saade GR, et al. First- and second-trimester evaluation of risk for Down syndrome. Obstet Gynecol 2007; 110: 1017.
  • 86
    Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57 (RR-8): 120.
  • 87
    Centers for Disease Control and Prevention. Chronic hepatitis B virus: 2007 case definition. http://www.cdc.gov/ncphi/disss/nndss/casedef/hepatitisbcurrent.htm. Accessed February 2009.